Longer detox might work better for prescription pain med addiction

Longer detox might work better for prescription pain med addiction
Small study compared varying treatment periods used with opioid-dependent patients.

(HealthDay)—A longer period of detoxification may be more effective for people being treated for addiction to prescription painkillers called opioids, according to a small new study.

Abuse of prescription opioids such as oxycodone, hydrocodone and hydromorphone is a major public health problem in the United States. The new 12-week study, which included 70 people undergoing outpatient treatment for opioid addiction, was published online Oct. 23 in the journal JAMA Psychiatry.

For the first two weeks, all the patients took buprenorphine, a medication used to treat opioid addiction. They were then randomly assigned to slowly reduce the dose of buprenorphine over one, two or four weeks, followed by treatment with naltrexone, a medication that blocks opioid strength.

Patients in the four-week group were more likely to stop abusing opioids than those in the one-week or two-week groups, according to a journal news release.

The findings suggest that some prescription opioid abusers may respond positively to outpatient treatment with followed by naltrexone while undergoing behavioral therapy [counseling], study authors wrote.

"Additional controlled studies are needed to better understand the parameters of efficacious treatments for [prescription ] dependence, as well as to identify the individuals for whom brief vs. longer-term treatments are warranted," concluded study authors Stacey Sigmon, of the University of Vermont, in Burlington, and colleagues.

More information: The U.S. National Institute on Drug Abuse has more about prescription drug abuse.

add to favorites email to friend print save as pdf

Related Stories

More opioid dependence treatment needed

Aug 06, 2013

A new report from Simon Fraser University researcher Bohdan Nosyk calls for the expansion of heroin and opioid medical treatment to stem the increase of overdose deaths.

FDA orders starker warnings on opioid painkillers

Sep 10, 2013

The Food and Drug Administration is requiring stronger warning labels on prescription painkillers like OxyContin, in the government's latest attempt to reduce overdose deaths caused by the long-acting medications.

Suboxone is most effective in treating painkiller addiction

Nov 07, 2011

Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today's ...

Opioid prescription is on the increase

Feb 12, 2013

More and more opioids are being prescribed for pain relief in Germany. This is the conclusion arrived at by Ingrid Schubert, Peter Ihle, and Rainer Sabatowski, whose study of a sample of inhabitants of the state of Hesse ...

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments